The Company

Welcome to Arana Therapeutics, a global company working in the fast-growing antibody therapeutics sector created by the merger of Peptech Limited and EvoGenix Limited.

Arana’s vision is to improve patients’ lives by developing new generation products and platforms for the treatment of inflammatory diseases such as rheumatoid arthritis and cancer.

The business is focused on expanding and accelerating the development of its internal clinical pipeline, leveraging its technology platforms to in-license new drug candidates and seeking commercial partners at the optimum stage of drug development. 

Arana’s strong cash position and experienced management team provide the company with a solid foundation to bring targeted therapeutics to the market, to improve the lives of patients and bring value to our shareholders.

Arana Therapeutics is based in Macquarie Park, Sydney, Australia (Headquarters & Clinical Development) with facilities in Melbourne (Technology Development) and San Francisco (Business Development). Arana Therapeutics trades on the Australian Stock Exchange as AAH and the AIM exchange in the UK under AAHx.